Photocure (PHO.OL) Stock Analysis & AI Equity Report
Photocure (PHO.OL) overview
Photocure (PHO.OL) stock analysis and AI equity research. For the latest completed financial year, 2025, Photocure reported revenue of NOK 533m and operating profit of NOK 110m; the year-end share price was 71.40 NOK and market capitalisation was NOK 1,904m. Photocure is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Photocure's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Photocure
Photocure ASA is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes Hexvix/Cysview, a blue light cystoscopy product used to improve detection and management of bladder tumors. The company sells directly in the United States and parts of Europe and works with partners in other markets.
Generate the Photocure report
Photocure is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Photocure and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.